Pulmonx reports Q3 EPS (34c), consensus (42c)

Reports Q3 revenue $21.5M, consensus $20.9M. “While our third quarter performance broadly met expectations, we feel there is a meaningful opportunity to leverage our operational foundation and refine execution to expand Zephyr Valve treatment volumes,” said Glen French, President and Chief Executive Officer of Pulmonx (LUNG). “We remain steadfast in our mission to improve the quality of life for patients with severe emphysema and are committed to acting with discipline to ensure our investments and operations are aligned with our goal to achieve sustainable, profitable growth.”